In-Depth Hepatorenal Syndrome Treatment Market Report: Business Trends, Growth Factors, and Forecast to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Hepatorenal Syndrome Treatment Market Heading Into 2029?
Over the past few years, the market for hepatorenal syndrome treatment has been expanding consistently. The market is forecasted to increase from $14.49 billion in 2024 to $15.17 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.6%. Several factors contributed to this growth during the historic period, including the expansion of the automotive industry, needs of the aerospace sector, better use of materials, enhanced mechanical properties, strict industry standards, and gains in efficiency and precision.
In the coming years, the hepatorenal syndrome treatment market is poised for robust growth. By 2029, it is projected to expand to “$19.57 billion with a 6.6% compound annual growth rate (CAGR). This anticipated growth can be ascribed to a surge in renewable energy projects, heightened need for high-performance alloys, an emphasis on sustainable production methods, further exploration in the oil and gas sector, and a rise in demand for high-performing components. Dominant trends forecasted for this period include the incorporation of industry 4.0 technologies, breakthroughs in forging techniques research, tailoring for specific uses, automation of forging procedures, and novel developments in heating and cooling technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10414&type=smp
Which Factors Are Pushing The Hepatorenal Syndrome Treatment Market Forward?
The hepatorenal syndrome treatment market’s expansion is anticipated to be fuelled by a rise in cases of liver damage or cirrhosis. In its advanced form, cirrhosis results in irreversible replacement of functional liver tissue with scar tissue. The goal of treating hepatorenal syndrome is to maintain kidney function in the patient while alleviating the disorder’s symptoms and harmful effects. These techniques might contribute to better overall health and prepare you for potential liver transplant surgery. For instance, data from the British Liver Trust, a UK-based charity gathered in July 2023, shows a significant upsurge in liver disease hospitalizations in England. There was a 22% increase in just one year, with the total count jumping from 67,458 in 2021 to 82,290 in the fiscal year 2022. Hence, the rising prevalence of patients suffering from liver damage or cirrhosis is propelling the growth of the hepatorenal syndrome treatment market.
The hepatorenal syndrome treatment market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Type 1 Hepatorenal Syndrome: Intravenous Albumin, Vasopressors, Dialysis, Liver Transplantation
2) By Type 2 Hepatorenal Syndrome: Albumin Infusion, Midodrine, Octreotide, Liver Transplantation
What Are The Leading Trends And Opportunities In The Hepatorenal Syndrome Treatment Sector?
A noticeable trend on the rise in the hepatorenal syndrome treatment market is the escalation of research and development activities. To maintain their standing within the market, businesses involved in the hepatorenal syndrome treatment sector are amplifying their focus on research and development. An example of this is seen in Mallinckrodt Pharmaceuticals, an Ireland-headquartered company with a specialty in creating, producing, and distributing specialty therapies and products, and their announcement in September 2022 of FDA approval for Terlivaz. This injection assists adults afflicted with kidney issues related to hepatorenal syndrome. The Phase 3 CONFIRM trial, the largest prospective study (n=300) ever conducted to test the safety and efficiency of terlipressin for patients with HRS type 1 (HRS-1) in the U.S and Canada, was instrumental in the FDA’s endorsement. The primary endpoint of the CONFIRM trial was a successful and confirmed HRS Reversal which was marked by improvements in kidney function, eliminating the necessity for dialysis, and offering short-term survival (p=0.012).
Which Organizations Are Driving Progress In The Hepatorenal Syndrome Treatment Industry?
Major companies operating in the hepatorenal syndrome treatment market include BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences Limited, Ocelot Bio Inc., New Medicon Pharma Lab Private Limited, Arrowhead Pharmaceuticals, Stealth BioTherapeutics Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Catalyst Pharmaceuticals Inc., Bayer AG, Gilead Sciences Inc.
Which Region Is Expected To Experience The Highest Growth In The Hepatorenal Syndrome Treatment Industry?
North America was the largest region in the hepatorenal syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10414&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
